SCHEMBL6737403

SCHEMBL6737403

N#Cc1cccc(N)c1C[O]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
MAP2K1 Q02750 1/20 0.36
TSHR P16473 3/20 0.34
MCL1 Q07820 1/20 0.34
HPGD P15428 4/20 0.33
KDM4E B2RXH2 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
GAA P10253 3/20 0.33
HTT P42858 3/20 0.33
MEN1 O00255 2/20 0.33
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
HDAC1 Q13547 2/20 0.32
HDAC3 O15379 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6743455 0.85 CA1 (0.42) CA1CA2MAP2K1TSHRMCL1
SCHEMBL28190550 0.82 CYP3A4 (0.44) CYP3A4CYP1A2CYP2C9CYP2C19CA1
SCHEMBL6742592 0.80 CYP3A4 (0.43) CYP3A4CYP1A2CYP2C9CYP2C19CA1
SCHEMBL1375312 0.80 CYP3A4 (0.43) CYP3A4CYP1A2CYP2C9CYP2C19CA1
SCHEMBL29355884 0.79 CYP1A2 (0.40) CYP3A4CYP1A2CYP2C9CYP2C19CA1
SCHEMBL27941110 0.78 TSHR (0.43) CYP3A4CYP2C9CA1CA2TSHR
SCHEMBL6457239 0.77 CYP3A4 (0.41) CYP3A4CYP1A2CYP2C9CYP2C19MAP2K1
SCHEMBL6740953 0.76 TSHR (0.54) CYP3A4CYP1A2CYP2C9CYP2C19CA1
SCHEMBL250206 0.76 CYP3A4 (0.40) CYP3A4CYP1A2CYP2C9CYP2C19MAP2K1
SCHEMBL6089703 0.74 CYP3A4 (0.42) CYP3A4CYP1A2CYP2C9CYP2C19MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6689771-B2 TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-02-10 US disclosed
US-6610731-B2 Antiinflammatory BRISTOL-MYERS SQUIBB COMPANY 2003-08-26 US disclosed
US-6403632-B1 CYCLIC AMIDE DERIVATIVE BRISTOL MYERS SQUIBB PHARMA CO (US) 2002-06-11 US disclosed
US-6376665-B1 ANTIARTHRITIC AGENTS, ANTIINFLAMMATORY AGENTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-04-23 US disclosed
EP-1165500-A1 AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE Du Pont Pharmaceuticals Company (US) 2002-01-02 EP disclosed
WO-2000059874-A1 NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE DU PONT PHARMACEUTICALS COMPANY (US) 2000-10-12 WO disclosed
EP-1027332-A1 NOVEL LACTAM METALLOPROTEASE INHIBITORS Du Pont Pharmaceuticals Company (US) 2000-08-16 EP disclosed
US-6057336-A ANTIINFLAMMATORY AGENTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2000-05-02 US disclosed
WO-1999018074-A1 NOVEL LACTAM METALLOPROTEASE INHIBITORS Britol-Myers Squibb Pharma Company (US) 1999-04-15 WO disclosed